InVivo Therapeutics Holdings Corp. - NVIV STOCK NEWS

InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) has closed a registered direct offering, selling 154,000 shares of common stock and pre-funded warrants for 369,810 shares to a healthcare-focused institutional investor. Additionally, a private placement for 1,190,476 pre-funded warrants also occurred. Gross proceeds are approximately $9 million, intended for working capital and the potential commercialization of its Neuro-Spinal Scaffold device. The preferred investment options issued allow for purchase of 1,714,286 shares at $5.05 each, exercisable immediately.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) has entered into a definitive agreement to sell 523,810 shares through a registered direct offering and an additional 1,190,476 shares in a private placement. Gross proceeds are anticipated to reach approximately $9.0 million before fees. The offerings include unregistered preferred investment options for up to 1,714,286 shares at an exercise price of $5.05. Proceeds will mainly support general corporate activities and potential commercialization of the Neuro-Spinal Scaffold device. The offerings are set to close around October 11, 2022.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), focusing on spinal cord injury treatment, announced CEO Richard Toselli will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The company's management will engage in virtual one-on-one meetings with registered investors. Dr. Toselli's presentation will be accessible via webcast on the company's website starting September 12, 2022, at 7:00 am ET.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) has appointed Heather M. Hamel as Chief Legal Officer and General Counsel. Hamel, previously Vice President of Legal Affairs, will oversee legal and intellectual property functions, as well as business development and external communications. CEO Richard Toselli expressed confidence in Hamel's contributions during this pivotal time for the company, especially ahead of the INSPIRE 2.0 top-line data readout expected in early 2023. Hamel holds a dual B.S. in biochemistry and chemistry and has extensive experience in legal and biomaterials fields.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) announced the publication of a peer-reviewed manuscript in Neurosurgery, detailing patient outcomes from their 24-month follow-up in the INSPIRE 1.0 Study. This study evaluates the investigational Neuro-Spinal Scaffold™ for spinal cord injuries. The company is encouraged by the findings which support further investigation and has closed the INSPIRE 1.0 study. Enrollment for the INSPIRE 2.0 Study is complete, with topline data expected in Q1 2023, aimed at enhancing clinical evidence.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) has completed enrollment in its INSPIRE 2.0 Study, a 20-patient randomized trial aimed at enhancing clinical evidence for its Neuro-Spinal Scaffold™. The study consists of 10 subjects in each arm and is focused on patients with acute spinal cord injury. CEO Richard Toselli highlighted this achievement as a significant advancement and expects to report topline data in Q1 2023. Principal Investigator Kee Kim called the completion of enrollment a major milestone for spinal cord injury treatment.

InVivo Therapeutics Holdings Corp. announced a 1-for-25 reverse stock split effective April 26, 2022. This action aims to comply with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. Post-split, the authorized shares will decrease from 50 million to 2 million, reducing outstanding shares from approximately 34.3 million to about 1.4 million. Fractional shares will be rounded up, affecting stock options and incentive plans accordingly. The new CUSIP number will be CUSIP 46186M 605.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a clinical-stage biotechnology company focused on spinal cord injury treatments, announced that CEO Richard Toselli will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will offer insights into the company's developments and clinical programs. Attendees can access the webcast starting January 10 at 7:00 am ET and participate in one-on-one meetings with management. Founded in 2005, InVivo utilizes proprietary technology co-invented by renowned researchers from MIT and Boston Children's Hospital.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a company focused on spinal cord injury treatment, announced the participation of CEO Richard Toselli at the H.C. Wainwright Annual Global Investment Conference from September 13-15, 2021. The conference will be virtual, and a webcast of the presentation will be available on the company's Investor Relations page starting on September 13 at 7:00 am ET. Additionally, Dr. Toselli will engage in one-on-one meetings with registered investors during the event.